GUZI, Timothy, Kamil PARUCH and Michael DWYER. Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors. 2007.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
Name in Czech Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
Authors GUZI, Timothy, Kamil PARUCH and Michael DWYER.
Edition Number: US 2007/0072880 A1, Publisher: Unitedf States Patent Office, Place of publication: USA, Owner's name: Schering-Plough, 2007.
Other information
Original language English
Type of outcome Patent
Field of Study 30200 3.2 Clinical medicine
Country of publisher Ukraine
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Science
Keywords (in Czech) pyrazolopyrimidine; cyclin dependent kinase; inhibitor
Keywords in English pyrazolopyrimidine; cyclin dependent kinase; inhibitor
Tags Cyclin dependent kinase, inhibitor, pyrazolopyrimidine
Changed by Changed by: doc. Mgr. Kamil Paruch, Ph.D., učo 108413. Changed: 23/6/2009 16:53.
Abstract
Title compds. I [R2 = alkyl, alkynyl, alkynylalkyl, etc.; R3 = H, halo, alkyl, etc.; R4 = H, halo or alkyl; R5 = (un)substituted aryl which may optionally be fused with one or more heteroaryl], and their pharmaceutically acceptable salts, are prepd. and disclosed as inhibitors of cyclin dependent kinases (CDKs). Thus, e.g., II (R = H) was prepd. by substitution of III (prepn. given) with aniline, followed by deprotection. In in vitro kinase assays, II (R = pyrazo-1-yl) was found to possess an IC50 = 0.2 (.mu.M). Further disclosed are pharmaceutical compns. contg. I, methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns.
Abstract (in Czech)
viz Anotace
PrintDisplayed: 2/8/2024 23:33